Financing ·
Arcus Biosciences raises $269.7M from selling 16.43M shares at $17.50
RCUSArcus Biosciences, Inc.
On October 21, 2026, Arcus Biosciences entered into an underwriting agreement to sell 14,285,715 shares of common stock at a public offering price of $17.50 per share. The company granted the underwriters an option to purchase up to an additional 2,142,857 shares. On October 23, 2026, the offering closed with the full exercise of the over-allotment option, resulting in the sale and issuance of 16,428,572 shares. The company received net proceeds of approximately $269.7 million after deducting underwriting discounts and estimated offering expenses. Arcus Biosciences operates in the biotechnology industry, focusing on the discovery and development of immunotherapies for cancer.